ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08905
-0,04%
Bitcoin
67.059,82
0,18%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Hillstream BioPharma Inc (HILS)

  7. Hillstream BioPharma Inc (HILS) News

HILS

Hillstream BioPharma (HILS)

Hillstream BioPharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:HILS
DatumZeitQuelleÜberschriftSymbolFirma
22/03/202416h12Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:HILSHillstream BioPharma Inc
22/03/202416h08Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:HILSHillstream BioPharma Inc
21/03/202422h27Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:HILSHillstream BioPharma Inc
21/03/202422h25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:HILSHillstream BioPharma Inc
25/09/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HILSHillstream BioPharma Inc
21/09/202315h35GlobeNewswire Inc.Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceNASDAQ:HILSHillstream BioPharma Inc
12/09/202314h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HILSHillstream BioPharma Inc
11/09/202317h51GlobeNewswire Inc.Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic PruritisNASDAQ:HILSHillstream BioPharma Inc
08/09/202320h30GlobeNewswire Inc.Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13NASDAQ:HILSHillstream BioPharma Inc
30/08/202323h22Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:HILSHillstream BioPharma Inc
30/08/202323h20Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:HILSHillstream BioPharma Inc
18/08/202323h15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:HILSHillstream BioPharma Inc
11/08/202322h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HILSHillstream BioPharma Inc
09/08/202314h47GlobeNewswire Inc.Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023NASDAQ:HILSHillstream BioPharma Inc
20/07/202314h00GlobeNewswire Inc.Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215NASDAQ:HILSHillstream BioPharma Inc
17/07/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HILSHillstream BioPharma Inc
11/07/202323h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HILSHillstream BioPharma Inc
10/07/202314h47GlobeNewswire Inc.Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and BiologicsNASDAQ:HILSHillstream BioPharma Inc
06/07/202314h30GlobeNewswire Inc.Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian CancersNASDAQ:HILSHillstream BioPharma Inc
20/06/202322h55Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:HILSHillstream BioPharma Inc
16/06/202322h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:HILSHillstream BioPharma Inc
22/05/202312h01Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:HILSHillstream BioPharma Inc
22/05/202312h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:HILSHillstream BioPharma Inc
22/05/202312h01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:HILSHillstream BioPharma Inc
16/05/202322h16Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:HILSHillstream BioPharma Inc
15/05/202322h23Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:HILSHillstream BioPharma Inc
15/05/202322h21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:HILSHillstream BioPharma Inc
15/05/202314h47GlobeNewswire Inc.Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly AndersonNASDAQ:HILSHillstream BioPharma Inc
02/05/202322h05GlobeNewswire Inc.Hillstream BioPharma Announces Closing of Public Offering of Common StockNASDAQ:HILSHillstream BioPharma Inc
02/05/202314h47GlobeNewswire Inc.Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry ConferencesNASDAQ:HILSHillstream BioPharma Inc
 Showing the most relevant articles for your search:NASDAQ:HILS

Kürzlich von Ihnen besucht

AMEX
PMR
Invesco Dynamic Retail ETF
BIT
F05700
Vontobel Financial Produ...
EU
INGQG
INGQG
TSX
NPS
Canadian Large Cap Leade...
USOTC
MINBY
MinebeaMitsumi (PK)
NASDAQ
ASKJ
Ask Jeeves
USOTC
CPXGF
Cineplex (PK)
BIT
F16930
Vontobel Financial Produ...
NASDAQ
APPD
APPDYNAMICS INC
TSX
GEI.R
Gibson Energy
AQSE
3EML.GB
WisdomTree Multi Asset I...
USOTC
VENAF
MicroAlgo (PK)
BIT
UB03T3
UniCredit Bank
BIT
GS0274
Goldman Sachs
BIT
UB3ZF5
Unicredit Bank
USOTC
MPFRY
Mapfre (PK)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten